- Korea Brain Research Institute maps how TDP-43 triggers neurotoxicity

- Boosting Trx1 levels reduces protein aggregation and oxidative stress

[123RF]
[123RF]

Scientists have identified a new mechanism by which brain cells die in patients with ALS and frontotemporal dementia.

The Korea Brain Research Institute said a research team led by senior researchers Kim Jae-kwang and Nam Min-yeop of its brain disease research division has mapped a previously unknown pathway through which TDP-43 protein aggregates — a hallmark shared by both ALS and frontotemporal dementia — damage neurons.

A defining feature of both diseases is the abnormal accumulation of TDP-43 protein clumps inside brain cells.

Under normal conditions, TDP-43 resides in the cell nucleus, where it regulates the processing of genetic information. In disease states, however, the protein escapes the nucleus and builds up in the cytoplasm, forming abnormal aggregates.

Such TDP-43 aggregates are observed in roughly 97 percent of ALS patients and roughly half of those with frontotemporal dementia. How exactly these protein clumps kill neurons had not been clearly established.

The research team focused on thioredoxin-1 (Trx1), an antioxidant protein that shields cells from oxidative damage.

Trx1 suppresses damage caused by reactive oxygen species inside cells and helps restore the function of oxidized proteins.

The team found that abnormally aggregated TDP-43 traps the messenger RNA needed to produce Trx1 inside the aggregates, blocking the protein's production.

This weakens the cell's antioxidant defenses and raises oxidative stress, ultimately impairing mitochondrial function — the cell's energy-producing machinery — and increasing neurotoxicity.

To address this, the researchers conducted experiments to raise Trx1 protein levels.

When Trx1 was increased in mouse neurons, TDP-43 aggregation and neurotoxicity both declined.

The same effect was confirmed in motor neurons derived from induced pluripotent stem cells carrying ALS-linked TDP-43 gene mutations. Elevating Trx1 expression significantly reduced oxidative stress and abnormal protein aggregation.

The joint research team behind the study. From left: Kim Cheon-a, a researcher at the Korea Research Institute of Bioscience and Biotechnology; Lee Sang-won, a professor at Korea University; Kim Sang-ryong, a professor at Kyungpook National University; and Nam Min-yeop and Kim Jae-kwang of the Korea Brain Research Institute. [Korea Brain Research Institute]
The joint research team behind the study. From left: Kim Cheon-a, a researcher at the Korea Research Institute of Bioscience and Biotechnology; Lee Sang-won, a professor at Korea University; Kim Sang-ryong, a professor at Kyungpook National University; and Nam Min-yeop and Kim Jae-kwang of the Korea Brain Research Institute. [Korea Brain Research Institute]

The research team also noted that Trx1 could serve as a common therapeutic target across a range of neurodegenerative diseases involving TDP-43 pathology — including Alzheimer's and Parkinson's disease — beyond ALS and frontotemporal dementia.

The findings are expected to open avenues for developing drugs that boost or sustain Trx1 expression, as well as early-diagnosis research using oxidative stress markers.

However, the results represent basic research confirming therapeutic potential at the cellular level. Further validation through animal models and clinical trials will be needed before the approach can be applied to patients.

"This shows that TDP-43 aggregates are not merely a byproduct of disease but an active aggressor that directly disables the cell's defense system," Kim Jae-kwang said. "We hope that restoring Trx1 will lead to a new treatment strategy for ALS and other TDP-43-related neurodegenerative diseases."

The study was conducted in collaboration with Kim Cheon-a of the Korea Research Institute of Bioscience and Biotechnology, Lee Sang-won of Korea University and Kim Sang-ryong of Kyungpook National University.

The findings were published in the international journal Redox Biology.


nbgkoo@heraldcorp.com